Search

Your search keyword '"R. Cayla"' showing total 20 results
Start Over Author "R. Cayla"
20 results on '"R. Cayla"'

2. La quadrithérapie bismuthée est supérieure au traitement séquentiel pour l’éradication de Helicobacter pylori : résultats d’une étude comparative en routine

Author

P. Talbi, H. Lamouliatte, Frank Zerbib, S. Cazorla, Francis Mégraud, G. Fotsing, E. Chabrun, and R. Cayla

Subjects
Gynecology, medicine.medical_specialty, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, business
Abstract

L’objectif de l’etude est de comparer, en pratique quotidienne, le traitement sequentiel standard (inhibiteur de la pompe a protons [IPP] + amoxicilline puis clarithromycine-metronidazole) a la quadritherapie bismuthee (omeprazole + bismuth-tetracycline-metronidazole) dans une population non selectionnee atteinte d’infection a Helicobacter pylori. Trente-sept patients recevant le traitement sequentiel ont ete compares a 43 patients recevant la quadritherapie bismuthee. L’objectif principal etait le taux d’eradication de H. pylori. Les objectifs secondaires etaient d’analyser le niveau de resistance aux antibiotiques et les effets secondaires du traitement. En intention de traiter, les taux d’eradication obtenus avec la quadritherapie bismuthee et le traitement sequentiel sont respectivement de 86 % et 67,6 % (p=0,048), et de 90,2 % et 71,4 % en analyse per protocole (p=0,035). Avec le traitement sequentiel, les echecs therapeutiques sont lies dans 66,7 % des cas a une resistance a la clarithromycine et/ou au metronidazole et, avec la quadritherapie bismuthee, dans 75 % des cas a une resistance au metronidazole. Aucun effet secondaire lie a l’utilisation du bismuth n’est survenu. Dans cette etude francaise realisee en routine, la quadritherapie bismuthee s’avere significativement superieure au traitement sequentiel. Ces resultats en font le traitement de premiere intention des infections a H. pylori.

Published
2015
Full Text
View/download PDF

3. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients

Author

Frank Zerbib, H Lamouliatte, B Sawan, Nathalie Broutet, C Lenk, B Carles, Francis Mégraud, A de Mascarel, and R. Cayla

Subjects
Adult, Male, medicine.medical_specialty, Atrophic gastritis, Gastroenterology, Statistics, Nonparametric, Helicobacter Infections, Atrophy, Internal medicine, Gastroscopy, Biopsy, Gastric mucosa, medicine, Humans, Aged, Probability, Retrospective Studies, Analysis of Variance, Helicobacter pylori, Hepatology, biology, medicine.diagnostic_test, business.industry, Intestinal metaplasia, Middle Aged, Anti-Ulcer Agents, biology.organism_classification, medicine.disease, Anti-Bacterial Agents, Treatment Outcome, medicine.anatomical_structure, Gastric Mucosa, Duodenal Ulcer, Gastritis, Duodenum, Drug Therapy, Combination, Female, medicine.symptom, business, Follow-Up Studies
Abstract

Objectives The aim of this study was to assess the consequences of prolongedHelicobacter pylorieradication on gastric antral mucosa in duodenal ulcer patients. Patients and methods Forty-three duodenal ulcer patients with confirmedH. pylorieradication after one year of follow-up were included in this retrospective study. BeforeH. pylorieradication and during the follow-up, four antral prepyloric biopsy samples were taken for histopathological examination and culture. Patients and methods Histopathological lesions were graded semi-quantitatively according to the updated Sydney System for activity, chronic inflammation, glandular atrophy and intestinal metaplasia (IM), as well as presence of lymphoid follicles. Results After a mean follow-up of 43 ± 23 months,H. pylorieradication statistically improved all gastritis scores, including the atrophy score and the lymphoid follicle score but excluding the IM score.H. pylorieradication resulted in normalization of gastric mucosa in 51.2% of patients and a significantly lower proportion of patients with non-atrophic gastritis and atrophic gastritis without IM. Atrophy totally disappeared in 16/29 patients (55.2%) in whom IM was absent. No predictive factor for regression of atrophy or normalization of gastric mucosa was identified. Conclusion In duodenal ulcer patients, prolonged absence (more than one year) ofH. pylorican lead to normalization of the antral mucosa and the disappearance of mucosaassociated lymphoid tissue, as well as the regression of antral atrophy. Long-term studies involving selected patients with atrophy and IM which persist afterH. pylorieradication are needed to determine the potential benefits of treatingH. pylorigastritis with regard to gastric cancer prevention.Eur J Gastroenterol Hepatol12:719-725

Published
2000
Full Text
View/download PDF

4. Dual Therapy Using a Double Dose of Lansoprazole With Amoxicillin Versus Triple Therapy Using a Double Dose of Lansoprazole, Amoxicillin, and Clarithromycin to Eradicate Helicobacter pylori Infection: Results of a Prospective Randomized Open Study

Author

Francis Mégraud, S. Forestier, H Lamouliatte, R. Cayla, Frank Zerbib, M Joubert-Collin, and A de Mascarel

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Lansoprazole, Gastroenterology, 2-Pyridinylmethylsulfinylbenzimidazoles, Helicobacter Infections, Pharmacotherapy, Clarithromycin, Internal medicine, medicine, Humans, Prospective Studies, Stomach Ulcer, Aged, Antibacterial agent, Chemotherapy, Helicobacter pylori, Hepatology, biology, business.industry, Amoxicillin, Middle Aged, Anti-Ulcer Agents, biology.organism_classification, Duodenal Ulcer, Drug Therapy, Combination, Female, Gastritis, medicine.symptom, business, Omeprazole, medicine.drug
Abstract

Objectives: The eradication of Helicobacter pylori is recommended in duodenal ulcer disease. The aim of this randomized open trial was to evaluate and compare H. pylori eradication and safety after a dual therapy consisting of lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) versus a triple therapy consisting of lansoprazole (30 mg b.i.d.), amoxicillin (1 g b.i.d.), and clarithromycin (500 mg b.i.d.) administered from day 1 to day 14. Methods : All patients with an ulcer received lansoprazole (30 mg) from day 15 to day 28. H. pylori status was determined from antral biopsies using histology, culture, and polymerase chain reaction (PCR) upon inclusion and 1-3 months after the end of the treatment. Results: Of the 50 patients included in the study, five did not adhere to the protocol. H. pylon eradication was obtained in 37.5% of the patients receiving lansoprazole-amoxicillin (n = 9/24) and in 95.2% of the patients receiving lansoprazole-amoxicillin.clarithromycin (n = 20/21, p < 0.0002). Minor side effects appeared in 8.3% of the cases during dual therapy (n = 2/24) and in 52% during triple therapy (n = 13/22, p < 0.001). These side effects consisted mainly of diarrhea and a metallic taste. Conclusion: Concommitant administration of double doses of lansoprazole with amoxicillin and clarithromycin is very efficacious against H. pylori infection compared with dual therapy.

Published
1998
Full Text
View/download PDF

5. Treatment

Author

C. S. Goodwin, B. Worsley, E. Pillai, V. Willems, H. D. Janisch, H. Langmaack, P. Sanchez, M. Alcalde, A. Lancho, P. Carpintero, R. Garcia, J. M. Pajares, P. Ya. Grigoriev, V. A. Isakov, E. P. Iakovenko, A. V. Iakovenko, K. Vogt, H. Hahn, I. H. Rehmann, M. Hedding-Eckerich, J. Blessing, G. M. Sobala, D. A. F. Lynch, B. Gallacher, M. F. Dixon, A. T. R. Axon, E. Bayerdörffer, G. Mannes, A. Sommer, W. Höchter, J. Weingart, R. Hatz, S. Miehlke, N. Lehn, G. Ruckdeschel, P. Dirschedl, M. Stolte, R. J. Adamek, M. Wegener, S. Birkholz, W. Opferkuch, G. H. Rühl, B. Wedmann, J. Labenz, E. Gyenes, G. H. R’hl, G. Börsch, R. Maieron, C. Rizzi, L. Zoratti, S. Andreoli, G. L. Da Broi, C. A. Beltrami, Zhuya Chengyl, Mou Yangiong, Hua Jiesong, Zhang Zhenhua, L. Bierti, E. G. Bolis, R. Di Battista, R. de Franchis, D. J. McAvinchey, M. Laurence, J. O’Riordan, M. Fantazi, M. Khawaja, E Bologna, M. Stroppiana, S. Peyre, R. Pulitano’, C. Sategna-Guidetti, E. Martin, T. Alarcön, J. C. Sanz, M. I. Jimonez, M. López-Brea, A. Burette, Y. Glupczynski, C. Deprez, F. Di Mario, M. Ferrana, G. Battaglia, P. Dotto, F. Vianello, G. A. Grasso, R. Fiocca, L. Villiani, O. Luinetti, A. Gianatti, R. Boldorini, M. Lazzaroni, G. Bianchi Porro, E. Trespi, M. Perego, C. Alvisi, B. Cesana, E. Solcia, R. P. H. Logan, R. R. Greaves, P. A. Gummett, M. M. Walker, Q. N. Karim, A. E. Duggan, J. H. Baron, J. J. Misiewicz, J. Lohmarm, L. H. H. Porst, J. Schönlebe, H. Riedel, F. Catalano, G. Rizzo, M. T. Ayoubi Khajekini, G. Branciforte, G. Inserra, A. Liberti, R. Suriani, C. Pallante, M. Ravizza, D. Mazzucco, D. Galliano, M. Malandrino, R. Oneglio, M. Colozza, E. Gaia, F. Sallio, D. Colozza, C. Grandis, G. B. Forte, M. E. Bottiglieri, R. Durasco, E. Grimaldi, P. Rocco, H. X. Xia, M. A. Daw, S. Sant, S. Beattie, C. T. Keane, C. A. O’Morain, H. Larsson, M. L. Berglund, P. Tessaro, R. Schiavon, M. G. Contini, T. Ton, L. Norberto, M. Cassaro, M. Rugge, M. Guido, R. Baffa, S. Gloriosa, F. Turatello, R. Naccarato, R. Collins, C. O’Moram, T. P. Kemmer, J. E. Dominguez-Munoz, H. Klingel, P. Malfertheiner, C. J. McCarthy, M. McDermott, D. Hourihane, C. O’Morain, M. T. Droy-Lefiax, B. Forestier, D. Guillomain, O. Plique, D. Brugmann, F. Mégraud, H. Lamouliatte, P. H. Bernard, R. Cayla, M. Mégraud, A. de Mascarel, A. Quintonl, A. McLaren, S. R. McDowell, A. A. McColm, C. O’Malley, J. Bagshaw, F. Bouffant, P. Marelli, L. Cellini, M. Campa, B. Dainelli, G. Soldani, M. del Tacca, G. Ferrini, G. Larcinese, N. Semperlotti, Gy. Molnar, A. Fzentmihalyi, A. Takats, G. Gero, J. Penyige, Gy. Mark, J. Martínez-Gómez, D. García-Novo, D. Acuña-Quinõs, M. Gimeno, S. Vigneri, R. Termini, A. Scialabba, G. Pisciotta, R. Gusmaroli, F. Milesi, P. Mule, M. Menegatti, C. Reale, J. Holten, and D. Vaira

Subjects
General Medicine
Published
1992
Full Text
View/download PDF

6. Microbiology

Author

N. Figura, R. J. Owen, M. Desai, P. F. Bayeli, L. Di HGregorio, M. Russi, R. A. Musmanno, P. R. Hawtin, D. Sharpstone, L. Hayes, A. Nøorgaard, H. Nielsen, L. P. Andersen, G. Geis, H. Leying, S. Suerbaum, W. Opferkuch, Y. Tonokatsu, T. Hayashi, Y. Fukuda, I. Yamamoto, S. Takami, T. Tamura, T. Shimoyama, M. Lopez-Brea, E. Martin, J. C.Sanz, M. Alonso, T. Alarcon, P. Michetti, N. Porta, L. Racine, J. P.Kraehenbuhl, A. L.Blum, L. Cardeñoso, A. P. Moran, A. Muotiala, L. Pyhälä, T. U. Kosunen, I. M. Helander, R. P. Roine, K. S. Salmela, J. Höök-Nikanne, M. Salaspuro, M. A. Daw, H. X. Xia, C. O’Morain, J. Lelwala-Guruge, F. Ascencio, Å. Ljungh, T. Wadström, Martina Ringnér, Kaija Valkonen, Marianne Paulsson, Åsa Ljungh, Torkel Wadström, I. Guldvog, T. Tannaes, G. Bukholm, H. Grav, R. Corinaldesi, A. Tucci, V. Stanghellini, S. Gasperoni, O. Varoli, G. F. Paparo, M. Gaetani, G. Cioffi, L. Barbara, M. O. Husson, D. Legrand, J. Mazurier, C. Caron, H. Leclerc, G. Spik, L. English, C. T. Keane, C. A. O’Morain, J. G. Fox, P. Correa, N. S. Taylor, N. Fatela, J. Melo Cristino, L. Monteiro, F. Ramalho, A. Saragoça, M.J Salgado, F. Mauch, G. Bode, H. Ditschuneit, P. Malfertheiner, M. Nilius, M. Pugliese, M. Moshkowitz, A. Gorea, M. Santo, S. Berger, T. Gilat, A. Belluzzi, D. Vaira, M. Campieri, S. Boschi, P. Gionchetti, P. Mulè, C. Brignola, F. Rizzello, M. Miglioli, H. Lamouliatte, D. Brugmann, R. Cayla, P. H. Bernard, F. Mégraud, A. Quinton, W. Bär, S. Wagner, E. Glen-Calvo, H. Koopmann, A. Szentmihalyi, Z. Radnai, Gy. Molnar, A. Bálint, and M. Ihász

Subjects
General Medicine
Published
1992
Full Text
View/download PDF

7. Abstract form for the Irish Journal of Medical Science v workshop on gastroduodenal pathology and Helicobacter pylori July 5th — 7th 1992 — Dublin, Ireland

Author

R. P. H. Logan, P. A. Gummett, M. M. Walker, Q. N. Karim, J. H. Baron, J. J. Misiewicz, G. Trieber, S. Walker, U. Klotz, A. Lozniewski, M. Weber, J. D. de Korwin, J. Floquet, M. C. Conroy, J. C. Burdin, G. A. Mannes, E. Bayerdörffer, W. Höchter, J. Weingart, W. Heldwein, A. Sommer, S. Müller-Lissner, W. Bomschein, S. Miehlke, M. Weinzierl, G. Ruckdeschel, H. von Wulffen, W. Köpcke, M. Stolte, S. J. Rune, T. Justesen, J. M. Hansen, T. G. Jensen, J. Eriksen, O. ø. Thomsen, J. Scheibel, O. Bonnevie, A. Bremmelgaard, M. Vilien, S. Knuhtsen, L. Elsborg, J. Hansen, K. Lauritsen, H. R. Wulff, D. Boixeda, S. Ballestero, R. Cantón, L. De Rafael, C. Martinm de Argila, M. J. Pozuelo, J. Sampedro, F. Baquero, P. Ya. Grigoriev, V. A. Isakov, E. P. Iakovenko, A. M. Hirschl, G. Brandstätter, B. Dragosics, E. Hentschel, M. Kundi, M. L. Rotter, K. Schütze, M. Taufer, M Neri, D Susi, I Bovani, R Pindo, F. Cuccurullo, L. G. V. Coelho, M. C. F. Passos, Y. Chausson, W. L. S. Vieira, F. J. Castro, J. M. M. Franco, M. L. M. Fernandes, L. P. Castro, C. Jonas, E. De Koster, M. Van Gossum, M. Depierreux, M. Cheval, M. Deltenre, E. Schütz, B. Bethke, A. Lee, E. Hegedus, J. O’Rourke, H. Larsson, S. Sjöstedt, B. Veress, C. E. Nord, G. M. Sobala, R. George, D. Tompkins, J. Finlay, A. Manning, S. Sant, H. X. Xia, M. Daw, J. Gilvarry, C. T. Keane, C. O’Morain, M. A. Rubio, B. Hegarty, A. L. Blum, E. Sulser, O. Stadelmann, N. Munoz, E. Buiatti, J. Vivas, W. Oliver, E. Cano, S. Peraza, D. Castro, V. Sanchez, O. Andrade, M. Benz, G. L. Mendz, S. L. Hazell, K. S. Salmela, R. P. Roire, J. Hook-Nikanne, T. U. Kosunen, M. Salaspur, C. J. Luke, D. D. J. Reynolds, C. W. Penn, G. Bode, F. Mauch, H. Ditschuneit, P. Malfertheiner, Richard L. Ferrero, Labigne Agnes, K. A. Eaton, S. Krakowka, H. L. T. Mobley, Li-Tai Hu, P. A. Foxall, A. P. Moran, I. M. Helander, C. Altman, I. Sobhani, C. Vissugaire, M. Migrant, J. P. Etienne, P. Sommi, V. Ricci, R. Fiocca, E. Cova, N. Figura, M. Romano, K. J. Ivey, E. Solcia, U. Ventura, M. Nilius, S. Schieffer, K. J. Hengels, H. Jablonowski, G. Strohmeyer, M. D. Cabrai, A. J. A. Barbosa, G. F. Lima Hr., C. A. Oliveira, J. M. Polak, G. Oderda, L. Villani, F. Altare, I. Morra, L. Miserendino, N. Ansaldi, M. F. Dixon, J. I. Wyatt, A. T. R. Axon, S. Beattie, H. Hamilton, S. Shabib, E. Cutz, B. Drumm, P. Sherman, L. A. Noach, T. Rolf, N. B. Bosma, M. P. Schwartz, J. Oosting, E. A. J. Rauws, G. N. J. Tytgat, A. Andrew, G. Nardone, F. d’Ormiento, M. Pontillo, A. J. Lobo, J. S. Uff, C. N. M. McNulty, S. P. Wilkinson, R. Suriani, C. Pallante, M. Ravizza, D. Galliano, D. Sallio, M. Malandrino, R. Oneglio, M. Colozza, D. Mazzucco, E. Gaia, S. Eidt, P. Vincent, F. Gottrand, D. Turck, M. Lecomte-Houcke, H. Leclerc, F. Bonvicini, S. Pretolani, M. Baraldini, D. Cilla, S. Baldinelli, E. Bazocchi, P. Acampora, N. Careddu, E. Brocchi, G. Gasbarrini, M. Joubert, N. Bazin, D. Thiaucourt, E. Protte, C. Gissler, A. Duprez, P. Merlin, S. Forestier, J. Labenz, E. Gyenes, G. H. Rühl, G. Börsch, G. Daskalopoulos, J. Carrick, R. Lian, S. Wagner, J. Bleck, M. Gebel, W. Bär, M. Manns, H. Lamouliatte, P. H. Bernard, R. Cayla, G. Vialette, A. Quinton, F. Mégraud, M. Lemaire, A. Quinten, A. De Mascarel, P. Webb, D. Forman, T. Knight, A. Wilson, S. Graves, D. Newell, J. Elder, E. Tonelli, M. R. A. Gatte, G. C. Ghironzi, G. Giulianelli, K. B. Bamford, J. S. A. Collins, J. Bickley, B. T. Johnston, S. Potts, V. Boston, R. J. Owen, J. Sloan, L. Basso, S. Lawlor, J. Clune, H. Szelényi, G. Stohmeyer, G. Macedo, I. Iglésias, A. P. Chaves, A. Loureiro, P. H. Katelaris, F. Seow, B. Lin, J. Napoli, D. B. Hones, M. C. Ngu, Natalia S. Akopyantz, Nikolay O. Bukanov, T. Ulf Westblom, Douglas E. Berg, J. F. Nyst, P. Denis, M. Buset, M. De Reuck, H. Nielsen, L. P. Andersen, Sabine Birkholz, Ulrich Knipp, Claudia Nietzki, Wolfgang Opferkuch, J. E. Crabtree, P. Peichl, I. J. D. Lindly, K. Deusch, C. Seifirth, A. Funk, I. Dahie, K. Reut, M. Classen, P. Gionchetti, D. Vaira, M. Campieri, E. Bertinelli, M. Menegatti, A. Belluzzi, C. Briognola, M. Miglioli, L. Barbara, A. Di Tommaso, M. T. De Magistris, M. Bugnoli, R. Petracca, A. Covacci, S. Censini, R. Rappuoli, S. Abrignani, M. C. Territo, K. L. Smela, J. R. Reeve, T. D. Lee, J. H. Walsh, D. Armellini, Z. Y. Xiang, H. M. Mitchell, P. J. Hu, Y. Y. Li, Z. J. Wang, S. M. Zhao, Q. Liu, M. Chen, G. G. Du, M. I. Filipe, P. I. Reed, M. E. Craanen, P. Blok, W. Dekker, E. Colombo, D. Redaelli, M. Santangelo, M. Spinelli, F. Farinati, F. Valiante, G. Delia Libera, B. Germanà, R. Baffa, M. Rugge, F. Vianelo, F. Di Mario, Pentti Sipponen, T. Rokkas, G. Popotheodorou, N. Kaldgeropoulos, C. Deprez, P. Galand, J. G. Fox, P. Wishnok, J. C. Murphy, S. Tannenbaum, P. Correa, Julie Parsonnet, C. Macor, G. L. Da Broi, C. Avellinio, R. Reifen, I. Rasooly, M. E. Millson, K. Murphy, J. E. Thomas, E. J. Eastham, E. Malorgio, D. Dell’Olio, T. P. Kemmer, J. E. Dominguez-Munoz, H. Klingel, M. R. A. Gatto, R. Olivieri, R. F. Bayeli, L. Abate, L. De Gregorio, J. Aziz, E. Esposito, C. Basagni, R. Guilluy, M. Rousseau-Tsangaris, J. L. Brazier, Torkel Wadstiöm, Tadeusz Tyszkiewicz, Per Bergenzaun, Karin Olsson, C. Birac, F. Tall, M. Albenque, A. Labigne, F. Megraud, R. A. Feldman, J. Deeks, Y. Glupczynski, A. Burette, H. Goossens, C. Van den Boore, J. P. Butzler, S. Veldhuyzen van Zanten, L. Best, G. Benzanson, D. Haldane, S. Hazell, N. P. Mapstone, D. A. F. Lynch, P. Quirke, D. E. Taylor, N. Chang, M. Eaton, E. Stockdale, S. M. Salama, L. Thompson, A. Cockayne, R. C. Spiller, E. Leen, E. Sweeney, H. Klann, R. Hatz, W. Bornschein, T. Simon, A. Eimiller, F. Bolle, C. Schweikert, W. Köpeke, S. F. Moss, A. E. Bishop, J. Calam, R. J. Cahill, H. Xia, J. Solnick, and L. Tompkins

Subjects
0303 health sciences, medicine.medical_specialty, biology, 030306 microbiology, business.industry, General surgery, General Medicine, Helicobacter pylori, biology.organism_classification, language.human_language, Duodenal ulcer, 03 medical and health sciences, Irish, language, Medicine, Optometry, Gastritis, medicine.symptom, business, Medical science, 030304 developmental biology
Published
1992
Full Text
View/download PDF

8. In-flight performance of the infrared atmospheric sounding interferometer (IASI) on METOP-A

Author

Thierry Phulpin, Denis Blumstein, G. Ponce, R. Fjortoft, F. R. Cayla, B. Tournier, and C. Buil

Subjects
Meteorology, Spectrometer, Astrophysics::Instrumentation and Methods for Astrophysics, Michelson interferometer, Infrared atmospheric sounding interferometer, law.invention, Interferometry, law, Calibration, Astronomical interferometer, Environmental science, Satellite, Astrophysics::Earth and Planetary Astrophysics, Radiometric calibration, Physics::Atmospheric and Oceanic Physics, Remote sensing
Abstract

The Infrared Atmospheric Sounding Interferometer (IASI) is a key element of the payload embarqued on METOP series of European meteorological polar-orbit satellites. IASI will provide very accurate data about the atmosphere, land and oceans for application to weather predictions and climate studies. IASI measurements will allow to derive temperature and humidity profiles with a vertical resolution of one kilometer and an average accuracy of one Kelvin and 10 % respectively. The IASI measurement technique is based on passive IR remote sensing using a precisely calibrated Fourier Transform Spectrometer operating in the 3.7 - 15.5 μm region and an associated infrared imager operating in the 10.3-12.5 μm region. The optical configuration of the sounder is based on a Michelson interferometer. Interferograms are processed by the onboard digital processing subsystem which performs the inverse Fourier Transform and the radiometric calibration. The integrated infrared imager allows the coregistration of the IASI soundings with AVHRR imager onboard METOP. The first METOP satellite was successfully launched on 19th of October 2006. This paper summarizes the IASI instrument radiometric, spectral and geometric performance as measured in orbit during the Calibration and Validation Phase. Instrument noise, spectral and radiometric calibration stability and spatial pointing accuracy are discussed as well as the performance of the Level 1 Processing chain.

Published
2007
Full Text
View/download PDF

9. Expected accuracy of the CO2 retrieval from IASI

Author

L. Chaumat, P. Prunet, B. Tournier, and F.-R. Cayla

Subjects
Troposphere, Data processing, Signal processing, Atmospheric measurements, Meteorology, Co2 concentration, Environmental science, Information analysis, Discrete Fourier transform, Water vapor, Remote sensing
Abstract

The expected accuracy of CO2 retrieval from IASI data is assessed. A particular signal processing is developed to efficiently exploit the CO2 information of the IASI spectrum, through a Discrete Fourier Transform (DFT) filtering. the DFT filtering allows to process the entire IASI CO2 information in about 50 data elements. An information content analysis indicates that, providing a climatological prior knowledge on the CO2 concentration variability and the meteorological forecast of temperature and water vapour profiles, the mean tropospheric CO2 concentration can be derived from a single IASI spectrum with an accuracy of about 2 parts per million by volume (ppmv), i.e., better than 1 %. the DFT filtering allows to process the entire IASI CO2 information in about 50 data elements. IASI; Remote-sensing; Atmosphere; Tropospheric CO2

Published
2004
Full Text
View/download PDF

10. [Treatment of Helicobacter pylori infection]

Author

H, Lamouliatte, R, Cayla, and F, Mégraud

Subjects
Treatment Outcome, Helicobacter pylori, Clarithromycin, Amoxicillin, Humans, Drug Therapy, Combination, Penicillins, Proton Pumps, Anti-Ulcer Agents, Anti-Bacterial Agents, Helicobacter Infections
Abstract

The recommended treatment of Helicobacter pylori infection is a seven-day course of the following regimen: a double dose proton-pump inhibitor (omeprazole 2 x 20 mg, or lansoprazole 2 x 30 mg, or pantoprazole 2 x 40 mg), associated with 2 antibiotics (amoxicillin 2 x 1,000 mg, clarithromycin 2 x 500 mg). Eradication rate is around 65%. Main causes of failure are antibiotic resistance, bad compliance, early termination of therapy due to adverse events. A second line treatment is possible with substitution of clarithromycine by metronidazole (3 x 500 mg), a longer duration of treatment (14 days) and sometimes a quadritherapy with bismuth (not available in France).

Published
2000

11. [How to eradicate Helicobacter pylori?]

Author

R, Cayla

Subjects
Helicobacter pylori, Clarithromycin, Imidazoles, Amoxicillin, Humans, Drug Resistance, Microbial, Drug Therapy, Combination, Proton Pump Inhibitors, Penicillins, Proton Pumps, Anti-Ulcer Agents, Anti-Bacterial Agents, Helicobacter Infections
Published
1996

12. [Idiopathic periaortic fibrosis: a difficult diagnosis in internal medicine]

Author

A, Sebban, J, Constans, P, Pheline, J F, Desson, L, Agron, D, Hamdi, A, Le Mouroux, R, Cayla, D, Néau, and J C, Baste

Subjects
Aged, 80 and over, Male, Internal Medicine, Humans, Retroperitoneal Fibrosis, Middle Aged, Tomography, X-Ray Computed, Magnetic Resonance Angiography, Aged
Abstract

Peri-aortitis retroperitoneal fibrosis is characterized by a reaction of a variable inflammatory nature while constricting the organs crossing the retroperitoneal space, notably the ureters and the blood vessels. It is difficult to diagnose such a rare disease. We bring about here six cases of periaortic retroperitoneal fibrosis diagnosed from systemic, digestive, urinary or vascular signs. Early diagnosis is often difficult and is shown to be established after an average of three months investigation. The average age of these patients, all of the male sex, is 58 years old (54 to 90). In the six cases this disease appears to be idiopathic even though in two cases it is associated to giant temporal arteritis and polymyalgia rheumatica. TDM remains the best diagnostic tool to point out the existence of this fibrosis, to observe its evolution and to investigate for any extension of the disease. The etiology of this fibrosis remains a mysterious one; however an immunologic origin has been suggested. Medical treatment by corticosteroids is often successful but the long term evolution of the disease is still uncertain.

Published
1994

13. IASI Infrared Interferometer for Operations and Research

Author

F-R. Cayla

Subjects
Horizontal resolution, Interferometry, Meteorology, Infrared, Payload, Resolution (electron density), Fourier transform spectrometers, Environmental science, Trace gas, Remote sensing
Abstract

The paper presents the high-resolution infrared interferometer being developed, in cooperation between France and Italy, to meet the needs of meteorology and atmospheric sciences in temperature, humidity profiles, and to provide limited information on trace gas abundance’s. The instrument is planned for launch as part of the meteorological payload onboard the European Polar Platform POEM-1. Presently in phase B, this Fourier transform spectrometer will provide spectra of high radiometric quality at 0.25 cm-1 resolution from 15.5 to 3.4 micrometers, with global coverage twice per day at 25 km horizontal resolution.

Published
1993
Full Text
View/download PDF

15. Triple therapy with proton pump inhibitor - amoxicillin and clarithromycin for Helicobacter pylori eradication

Author

Frank Zerbib, Francis Mégraud, R. Cayla, and Hervé Lamouliatte

Subjects
medicine.medical_specialty, Hepatology, biology, medicine.drug_class, business.industry, Gastroenterology, Proton-pump inhibitor, Helicobacter pylori, Amoxicillin, biology.organism_classification, Internal medicine, Clarithromycin, medicine, business, medicine.drug
Published
1995
Full Text
View/download PDF

16. Measures of Stratospheric Displacements from Satellite Data

Author

S. Muller, F. R. Cayla, and J. P. Jullier

Subjects
chemistry.chemical_compound, Ozone, chemistry, Planck's law, Satellite data, Radiative transfer, Transmittance, Environmental science, Total ozone, Remote sensing
Abstract

Ozone transmittance at 9.6 µm is retrieved from IR radiances measured by TOVS (Tiros Operational Vertical Sounder) on NOAA satellites, using the radiative transfer equation

Published
1985
Full Text
View/download PDF

17. [Treatment of Helicobacter pylori infection].

Author

Lamouliatte H, Cayla R, and Mégraud F

Subjects
Amoxicillin administration & dosage, Anti-Bacterial Agents administration & dosage, Anti-Ulcer Agents administration & dosage, Clarithromycin administration & dosage, Drug Therapy, Combination, Humans, Penicillins administration & dosage, Proton Pumps drug effects, Treatment Outcome, Amoxicillin therapeutic use, Anti-Bacterial Agents therapeutic use, Anti-Ulcer Agents therapeutic use, Clarithromycin therapeutic use, Helicobacter Infections drug therapy, Helicobacter pylori, Penicillins therapeutic use
Abstract

The recommended treatment of Helicobacter pylori infection is a seven-day course of the following regimen: a double dose proton-pump inhibitor (omeprazole 2 x 20 mg, or lansoprazole 2 x 30 mg, or pantoprazole 2 x 40 mg), associated with 2 antibiotics (amoxicillin 2 x 1,000 mg, clarithromycin 2 x 500 mg). Eradication rate is around 65%. Main causes of failure are antibiotic resistance, bad compliance, early termination of therapy due to adverse events. A second line treatment is possible with substitution of clarithromycine by metronidazole (3 x 500 mg), a longer duration of treatment (14 days) and sometimes a quadritherapy with bismuth (not available in France).

Published
2000

18. [How to eradicate Helicobacter pylori?].

Author

Cayla R

Subjects
Amoxicillin adverse effects, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Anti-Ulcer Agents adverse effects, Clarithromycin adverse effects, Clarithromycin therapeutic use, Drug Resistance, Microbial, Drug Therapy, Combination, Helicobacter Infections microbiology, Humans, Imidazoles adverse effects, Imidazoles therapeutic use, Penicillins adverse effects, Proton Pump Inhibitors, Proton Pumps adverse effects, Proton Pumps therapeutic use, Amoxicillin therapeutic use, Anti-Ulcer Agents therapeutic use, Helicobacter Infections drug therapy, Helicobacter pylori isolation & purification, Penicillins therapeutic use
Published
1996

19. [Idiopathic periaortic fibrosis: a difficult diagnosis in internal medicine].

Author

Sebban A, Constans J, Pheline P, Desson JF, Agron L, Hamdi D, Le Mouroux A, Cayla R, Néau D, and Baste JC

Subjects
Aged, Aged, 80 and over, Humans, Internal Medicine, Magnetic Resonance Angiography, Male, Middle Aged, Tomography, X-Ray Computed, Retroperitoneal Fibrosis diagnosis
Abstract

Peri-aortitis retroperitoneal fibrosis is characterized by a reaction of a variable inflammatory nature while constricting the organs crossing the retroperitoneal space, notably the ureters and the blood vessels. It is difficult to diagnose such a rare disease. We bring about here six cases of periaortic retroperitoneal fibrosis diagnosed from systemic, digestive, urinary or vascular signs. Early diagnosis is often difficult and is shown to be established after an average of three months investigation. The average age of these patients, all of the male sex, is 58 years old (54 to 90). In the six cases this disease appears to be idiopathic even though in two cases it is associated to giant temporal arteritis and polymyalgia rheumatica. TDM remains the best diagnostic tool to point out the existence of this fibrosis, to observe its evolution and to investigate for any extension of the disease. The etiology of this fibrosis remains a mysterious one; however an immunologic origin has been suggested. Medical treatment by corticosteroids is often successful but the long term evolution of the disease is still uncertain.

Published
1994

20. [Follicular gastritis in adults. Relations with Helicobacter pylori, histological and endoscopic aspects].

Author

Zerbib F, Vialette G, Cayla R, Rudelli A, Sauvet P, Bechade D, Seurat PL, and Lamouliatte H

Subjects
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biopsy, Chronic Disease, Endoscopy, Gastrointestinal, Female, Gastritis diagnostic imaging, Gastritis microbiology, Gastritis pathology, Helicobacter Infections diagnostic imaging, Helicobacter Infections microbiology, Helicobacter Infections pathology, Humans, Male, Middle Aged, Prevalence, Prospective Studies, Pyloric Antrum pathology, Radiography, Gastritis epidemiology, Helicobacter Infections epidemiology, Helicobacter pylori isolation & purification, Pyloric Antrum microbiology
Abstract

Follicular gastritis (FG) is characterized by lymphoid follicle hyperplasia in the gastric mucosa. The aim of this prospective study was to determine the prevalence of FG in adults, their relation to Helicobacter pylori infection, and their histological and endoscopic features. Of 445 patients (379 men, 66 women), 36.4 years old (range: 18-86), FG was detected in 63 patients (14.2%). This was highly significantly associated with H. pylori infection: 49/138 infected patients (35.5%) versus 14/307 non infected patients (4.6%) (P < 0.001). None of the histological features of the antral mucosa were correlated with FG. The prevalence of FG in patients less than 20 years old (in 45.4%) and between 20 and 40 years (in 41.3%) was higher than in patients aged from 40 to 60 years (in 33%) and older than 60 years (in 23%) (no significant difference). No one endoscopic feature of the gastric mucosa was predictive of the presence of FG. We conclude that FG is highly correlated with H. pylori infection and represents a local immune response to bacterial antigens. Their occurrence is probably multifactorial and related to age, duration of infection, bacterial strains, host immune status.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results